« Back
Home /
Tenapanor

Tenapanor

Manufacturer	MedChem Express
Category	Oncology Metabolism Cholesterol & Lipid Metabolism Lipoprotein Receptors & Associated Proteins Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Amount	50 mg
Item no.	HY-15991-50mg
Targets	Sodium Channel
CASRN	1234423-95-0
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	1145.05
Clinical_Information	Launched
Manufacturers Research_Area	Metabolic Disease
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturers Target	Na+/H+ Exchanger (NHE)
Pathway	Membrane Transporter/Ion Channel
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15991-50mg-safety-datasheet.pdf